IBRX Stock Poised for Breakout Quarter: Anktiva Launches Phase 2 Long COVID Trial Amid European Expansion Plans
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 30 2026
0mins
Source: stocktwits
Phase 2 Long COVID Study Launch: The company has initiated a Phase 2 study to assess the effectiveness of Anktiva in improving recovery from long COVID by restoring immune cells, with plans to enroll about 20 participants and complete the study by October.
Expansion Beyond Cancer: Anktiva's platform has expanded its applications beyond cancer treatments to include severe pneumonia, sepsis, and acute respiratory distress syndrome, indicating a broader potential for immune activation therapies.
Stock Performance and Market Sentiment: Shares of ImmunityBio (IBRX) have surged over 270% this year, significantly outperforming the S&P Biotech ETF, reflecting positive market sentiment and renewed interest in the company's therapies.
Regulatory Progress and Future Plans: The therapy has been added to approved drug lists for bladder cancer and is being positioned as a recommended option for patients who do not respond to standard therapies, with ongoing efforts to expand its use in various diseases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.430
Low
5.00
Averages
7.33
High
9.00
Current: 7.430
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ImmunityBio Presents ANKTIVA and BCG Treatment Comparison Data
- Efficacy Comparison Analysis: ImmunityBio will present comparative results of ANKTIVA plus BCG against other therapies at the 2026 American Urological Association Annual Meeting, aiming to enhance treatment options for patients with BCG-unresponsive non-muscle invasive bladder cancer, thereby improving clinical decision-making effectiveness.
- Innovative Treatment Exploration: Research on recombinant BCG (rBCG) in BCG-naïve patients indicates potential for earlier line treatment, reflecting the company's ongoing efforts to address BCG supply constraints and expand treatment options for patients.
- Clinical Trial Updates: ImmunityBio is advancing a randomized controlled trial for BCG-naïve patients to evaluate the safety and efficacy of rBCG, which will provide clinicians with a more comprehensive treatment framework to improve patient outcomes.
- IL-15 Mechanism Discussion: Founder Dr. Soon-Shiong will discuss the role of IL-15 in urological oncology at the meeting, emphasizing its importance in activating T cells and NK cells, further driving research advancements in bladder and prostate cancers.
See More
ImmunityBio Faces Class Action Lawsuit and FDA Warning
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against ImmunityBio, alleging securities fraud and unlawful business practices by the company and certain executives, with investors needing to apply as Lead Plaintiff by May 26, 2026, highlighting serious governance concerns.
- FDA Warning Revealed: On March 24, 2026, a warning letter from the FDA became public, asserting that ImmunityBio continued to promote its bladder cancer drug Anktiva misleadingly, despite prior warnings, which could lead to stricter regulatory scrutiny and legal repercussions for the company.
- Stock Price Plummets: Following the FDA warning, ImmunityBio's stock price fell by 21.12%, dropping $1.99 to close at $7.41 per share on March 24, 2026, reflecting a pessimistic outlook from the market regarding the company's future prospects.
- Law Firm's Reputation: Pomerantz LLP is recognized as a leading firm in securities class action litigation, with over 85 years of experience advocating for victims of securities fraud, demonstrating its significant influence and expertise in the legal field through numerous successful recoveries for class members.
See More
ImmunityBio Faces Securities Class Action Lawsuit
- Lawsuit Background: ImmunityBio is facing a securities class action lawsuit due to misleading statements made by its Chief Scientific Officer regarding Anktiva's efficacy during a podcast, involving investors from January 19 to March 24, 2026, highlighting significant deficiencies in the company's information disclosure practices.
- FDA Warning Impact: The FDA issued a warning letter to ImmunityBio, indicating that its promotional materials contained false or misleading information, which led to a more than 21% drop in the company's stock price on March 24, 2026, erasing nearly $2 billion in market capitalization and severely impacting investor confidence.
- Investor Rights Protection: Hagens Berman is investigating whether ImmunityBio intentionally misled investors, urging those who suffered significant losses to submit claims, reflecting a strong concern for corporate compliance and transparency.
- Public Health Risks: The FDA emphasized that ImmunityBio's promotional materials grossly misrepresent the benefits of Anktiva, potentially impacting patient health, indicating that the company must exercise greater caution in product promotion to avoid legal and reputational risks.
See More
Faruqi & Faruqi Investigates Investor Losses in ImmunityBio Securities
- Legal Investigation Initiated: Faruq & Faruq LLP is investigating ImmunityBio, focusing on investors who purchased securities between January 19, 2026, and March 24, 2026, to assess potential legal claims against the company.
- Investor Rights Reminder: The firm reminds investors that May 26, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, emphasizing the importance of timely action to protect their rights.
- Direct Contact Channels: Investors who suffered losses are encouraged to contact Faruq & Faruq partner Josh Wilson directly, with multiple contact options provided, reflecting the firm's commitment to client service.
- Market Impact: This investigation may negatively affect ImmunityBio's stock price, prompting investors to monitor developments closely to adjust their investment strategies accordingly.
See More
ImmunityBio Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against ImmunityBio for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5, concerning securities purchased between January 19, 2026, and March 24, 2026.
- False Statements Allegation: The complaint alleges that ImmunityBio made false and misleading statements regarding the capabilities of its Anktiva drug, resulting in investor losses once the market learned the truth about the company's public statements.
- Investor Rights Protection: Affected investors are encouraged to contact the Schall Law Firm before May 26, 2026, to participate in the lawsuit and seek recovery of their losses, highlighting the firm's specialization in securities class actions and shareholder rights litigation.
- Lawsuit Status Explanation: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who choose not to act will be considered absent class members, underscoring the importance of participation.
See More
ImmunityBio's New Research to Influence Treatment Choices
- New Research Presentation: ImmunityBio will present new research on intravesical recombinant BCG for patients who have not previously received BCG at the American Urological Association Annual Meeting, potentially providing fresh insights into treatment choices for non-muscle-invasive bladder cancer, thereby influencing clinical decision-making.
- Significant Sales Growth: Anktiva's preliminary Q1 net product revenue reached $44.2 million, marking a 168% year-over-year increase, with full-year 2025 revenue projected to climb to $113 million, showcasing the strong market performance and growth potential of this immunotherapy.
- Clinical Data Updates: The company plans to share insights on the role of IL-15 in urological cancers, including its mechanism of activating T cells and natural killer cells, alongside current clinical data, aimed at advancing research for BCG-naïve patients.
- Positive Market Reaction: IBRX stock has been a standout performer this year, gaining over 250%, and despite retail sentiment shifting to neutral, investors remain optimistic about the future outlook.
See More
ImmunityBio Presents ANKTIVA and BCG Treatment Comparison Data
- Efficacy Comparison Analysis: ImmunityBio will present comparative results of ANKTIVA plus BCG against other therapies at the 2026 American Urological Association Annual Meeting, aiming to enhance treatment options for patients with BCG-unresponsive non-muscle invasive bladder cancer, thereby improving clinical decision-making effectiveness.
- Innovative Treatment Exploration: Research on recombinant BCG (rBCG) in BCG-naïve patients indicates potential for earlier line treatment, reflecting the company's ongoing efforts to address BCG supply constraints and expand treatment options for patients.
- Clinical Trial Updates: ImmunityBio is advancing a randomized controlled trial for BCG-naïve patients to evaluate the safety and efficacy of rBCG, which will provide clinicians with a more comprehensive treatment framework to improve patient outcomes.
- IL-15 Mechanism Discussion: Founder Dr. Soon-Shiong will discuss the role of IL-15 in urological oncology at the meeting, emphasizing its importance in activating T cells and NK cells, further driving research advancements in bladder and prostate cancers.
See More
ImmunityBio Faces Class Action Lawsuit and FDA Warning
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against ImmunityBio, alleging securities fraud and unlawful business practices by the company and certain executives, with investors needing to apply as Lead Plaintiff by May 26, 2026, highlighting serious governance concerns.
- FDA Warning Revealed: On March 24, 2026, a warning letter from the FDA became public, asserting that ImmunityBio continued to promote its bladder cancer drug Anktiva misleadingly, despite prior warnings, which could lead to stricter regulatory scrutiny and legal repercussions for the company.
- Stock Price Plummets: Following the FDA warning, ImmunityBio's stock price fell by 21.12%, dropping $1.99 to close at $7.41 per share on March 24, 2026, reflecting a pessimistic outlook from the market regarding the company's future prospects.
- Law Firm's Reputation: Pomerantz LLP is recognized as a leading firm in securities class action litigation, with over 85 years of experience advocating for victims of securities fraud, demonstrating its significant influence and expertise in the legal field through numerous successful recoveries for class members.
See More
ImmunityBio Faces Securities Class Action Lawsuit
- Lawsuit Background: ImmunityBio is facing a securities class action lawsuit due to misleading statements made by its Chief Scientific Officer regarding Anktiva's efficacy during a podcast, involving investors from January 19 to March 24, 2026, highlighting significant deficiencies in the company's information disclosure practices.
- FDA Warning Impact: The FDA issued a warning letter to ImmunityBio, indicating that its promotional materials contained false or misleading information, which led to a more than 21% drop in the company's stock price on March 24, 2026, erasing nearly $2 billion in market capitalization and severely impacting investor confidence.
- Investor Rights Protection: Hagens Berman is investigating whether ImmunityBio intentionally misled investors, urging those who suffered significant losses to submit claims, reflecting a strong concern for corporate compliance and transparency.
- Public Health Risks: The FDA emphasized that ImmunityBio's promotional materials grossly misrepresent the benefits of Anktiva, potentially impacting patient health, indicating that the company must exercise greater caution in product promotion to avoid legal and reputational risks.
See More
Faruqi & Faruqi Investigates Investor Losses in ImmunityBio Securities
- Legal Investigation Initiated: Faruq & Faruq LLP is investigating ImmunityBio, focusing on investors who purchased securities between January 19, 2026, and March 24, 2026, to assess potential legal claims against the company.
- Investor Rights Reminder: The firm reminds investors that May 26, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, emphasizing the importance of timely action to protect their rights.
- Direct Contact Channels: Investors who suffered losses are encouraged to contact Faruq & Faruq partner Josh Wilson directly, with multiple contact options provided, reflecting the firm's commitment to client service.
- Market Impact: This investigation may negatively affect ImmunityBio's stock price, prompting investors to monitor developments closely to adjust their investment strategies accordingly.
See More
ImmunityBio Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against ImmunityBio for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5, concerning securities purchased between January 19, 2026, and March 24, 2026.
- False Statements Allegation: The complaint alleges that ImmunityBio made false and misleading statements regarding the capabilities of its Anktiva drug, resulting in investor losses once the market learned the truth about the company's public statements.
- Investor Rights Protection: Affected investors are encouraged to contact the Schall Law Firm before May 26, 2026, to participate in the lawsuit and seek recovery of their losses, highlighting the firm's specialization in securities class actions and shareholder rights litigation.
- Lawsuit Status Explanation: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who choose not to act will be considered absent class members, underscoring the importance of participation.
See More
ImmunityBio's New Research to Influence Treatment Choices
- New Research Presentation: ImmunityBio will present new research on intravesical recombinant BCG for patients who have not previously received BCG at the American Urological Association Annual Meeting, potentially providing fresh insights into treatment choices for non-muscle-invasive bladder cancer, thereby influencing clinical decision-making.
- Significant Sales Growth: Anktiva's preliminary Q1 net product revenue reached $44.2 million, marking a 168% year-over-year increase, with full-year 2025 revenue projected to climb to $113 million, showcasing the strong market performance and growth potential of this immunotherapy.
- Clinical Data Updates: The company plans to share insights on the role of IL-15 in urological cancers, including its mechanism of activating T cells and natural killer cells, alongside current clinical data, aimed at advancing research for BCG-naïve patients.
- Positive Market Reaction: IBRX stock has been a standout performer this year, gaining over 250%, and despite retail sentiment shifting to neutral, investors remain optimistic about the future outlook.
See More
